Welcome to PreCardix® Professional Resources. This section provides important information for healthcare providers on prescribing PreCardix® to patients. Content on this page has been reviewed by our Medical Advisory Board. If you have any additional questions about PreCardix®, please get in touch with us directly at PreCardix® Support.
PreCardix®: A Decade of Rigorous Research and Clinical Validation
PreCardix® represents the culmination of over ten years of dedicated research and development, focused on creating an effective, sustainable, and scientifically proven natural product to support blood pressure health.
This product’s efficacy is underpinned by two key clinical studies: the preliminary MARE study and the comprehensive Marealis 13TBHM trial, a peer-reviewed, double-blind, placebo-controlled, multicentre clinical trial. Conducted between 2012 and 2015, these studies involved over 220 male and female participants aged 30 to 75, providing a robust foundation of evidence for PreCardix®.
The clinical research demonstrated that the unique bioactive marine peptides (RSPC) derived from hydrolyzed shrimp shells (Pandalus borealis) in PreCardix® possess a potent ACE inhibiting mechanism of action. This mechanism was shown to produce a statistically significant improvement in blood pressure health in more than 89% of participants, often within just eight weeks.
Highlights of the Marealis 13TBHM study:
- 1,200 mg per day of unique bioactive marine peptides have a statistically significant effect on blood pressure health in adults with mild to moderate hypertension
- Angiotensin II levels were significantly reduced in the treatment group compared to baseline documenting the ACE-inhibiting action
- No serious adverse effects were reported by study participants, including hypotension, angioedema, dry cough, or hyperkalemia
- 89% of clinical trial participants experienced a significant effect on blood pressure health within eight weeks or less
- 43% of clinical trial participants experienced a change in blood pressure by over 10mmHg in eight weeks
- 24% of clinical trial participants experienced a change in blood pressure by over 15mmHg within eight weeks
For more information on PreCardix® clinical indications, safety and effectiveness, please review the resources below, including clinical research, product monographs, and FAQs.
For more information on PreCardix® clinical indications, safety and effectiveness, please review the resources below, including clinical research, product monographs, and FAQs.
Always consult with your health care provider before making changes to your blood pressure management plan. PreCardix® does not treat, cure or prevent medical conditions. Measure and monitor blood pressure regularly. Know the signs of heart attack and stroke. Do not take PreCardix® if you are pregnant, breastfeeding, have renal artery stenosis, history of angioneurotic edema, or shellfish allergy.
